INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Children's Oncology Group
Study ID
NCT01164163
Phase
PHASE1
Status
Completed

Conditions

  • Chronic Myeloproliferative Disorders
  • Leukemia
  • Myelodysplastic Syndromes
  • Myelodysplastic/Myeloproliferative Neoplasms
  • Unspecified Childhood Solid Tumor, Protocol Specific

Eligibility Criteria

Sex
ALL
Age
1 Year - 21 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: INCB18424 (Ruxolitinib) may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase 1 clinical trial is studying the side effects and best dose of INCB18424 in treating young patients with relapsed or refractory solid tumor, leukemia, or myeloproliferative disease.

Key Dates

Start date
Sep 30, 2010
Status verified
Oct 2014
Primary completion
Oct 31, 2014

Study Design

Enrollment
49 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (Ruxolitinib)

Primary Outcome Measure

Maximum-tolerated dose and/or recommended phase II dose [ Time Frame: 28 days ]

Locations (24)

FacilityCityStateZIPSite coordinators
UAB Comprehensive Cancer CenterBirminghamAlabama35294-
Children's Hospital of Orange CountyOrangeCalifornia92868-
UCSF Helen Diller Family Comprehensive Cancer CenterSan FranciscoCalifornia94115-
Children's Hospital Colorado Center for Cancer and Blood DisordersAuroraColorado80045-
Children's National Medical CenterWashington D.C.District of Columbia20010-2970-
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston CampusAtlantaGeorgia30322-
Children's Memorial Hospital - ChicagoChicagoIllinois60611-
Riley's Children Cancer Center at Riley Hospital for ChildrenIndianapolisIndiana46202-
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimoreMaryland21231-2410-
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral OfficeBethesdaMaryland20892-1182-
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer InstituteBostonMassachusetts02115-
C.S. Mott Children's Hospital at University of Michigan Medical CenterAnn ArborMichigan48109-0286-
Masonic Cancer Center at University of MinnesotaMinneapolisMinnesota55455-
Siteman Cancer Center at Barnes-Jewish Hospital - Saint LouisSt LouisMissouri63110-
Herbert Irving Comprehensive Cancer Center at Columbia University Medical CenterNew YorkNew York10032-
Cincinnati Children's Hospital Medical CenterCincinnatiOhio45229-3039-
Knight Cancer Institute at Oregon Health and Science UniversityPortlandOregon97239-3098-
Children's Hospital of PhiladelphiaPhiladelphiaPennsylvania19104-
Children's Hospital of Pittsburgh of UPMCPittsburghPennsylvania15213-
St. Jude Children's Research HospitalMemphisTennessee38105-
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - DallasDallasTexas75390-
Baylor University Medical Center - HoustonHoustonTexas77030-2399-
Children's Hospital and Regional Medical Center - SeattleSeattleWashington98105-
Midwest Children's Cancer Center at Children's Hospital of WisconsinMilwaukeeWisconsin53226-

Find similar trials in Birmingham, AL

By condition
Leukemia (other)
By specialty
OncologyBlood cancer
By research site
UAB Comprehensive Cancer Center· Birmingham, ALChildren's Hospital of Orange County· Orange, CAUCSF Helen Diller Family Comprehensive Cancer Center· San Francisco, CAChildren's Hospital Colorado Center for Cancer and Blood Disorders· Aurora, COChildren's National Medical Center· Washington D.C., DCAFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus· Atlanta, GA

Related Studies